← GRAIL, LLC overview

GRAIL, LLC vs Agilent: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GRAIL, LLC (GRAL)

Q3 2026
▲3▼1

FDA Panel Backs Galleri, But Lawsuits and Losses Persist

  • FDA Panel Backs Galleri An FDA advisory panel found Galleri safe and effective, moving it toward expected early-2027 approval and potential Medicare and private insurance coverage. This is a major step for future revenue.

    This is the most significant new positive event that could drive the stock higher.

  • Strong Q2 Volume and Revenue Growth Q2 test volume rose 35% to over 61,000 tests, and revenue grew 24%. This shows growing demand for Galleri, even though the test is not yet broadly covered by insurers.

    It provides concrete evidence of business momentum, a new positive data point for the quarter.

  • $110 Million Samsung Investment A $110 million investment from Samsung strengthened GRAIL's balance sheet, providing more cash to fund operations until Galleri gains approval and reimbursement.

    This new capital injection reduces near-term financial risk and supports the stock.

  • Lawsuits and Cash Burn Continue Securities fraud lawsuits over the failed NHS-Galleri trial keep piling up, with an August 4 lead-plaintiff deadline. GRAIL lost $110 million last quarter, and Galleri's ~$700 cost is still largely uncovered by insurers, so cash burn continues.

    These ongoing legal and financial pressures are the main negative forces weighing on the stock.

August 2026
▲3▼1

FDA Panel Backs Galleri, But Legal and Financial Risks Linger

  • FDA Panel Vote An FDA advisory panel voted that Galleri is safe and effective, a key step toward approval expected in early 2027. Approval would open Medicare and private insurance coverage, potentially boosting sales.

    This is the most significant positive event, directly impacting future revenue and stock sentiment.

  • Q2 Volume and Revenue Growth Q2 2026 results showed Galleri test volume up 35% to over 61,000 and revenue up 24%. The $110 million Samsung investment strengthened the balance sheet, supporting ongoing operations.

    Demonstrates underlying business momentum and improved financial position, key for investor confidence.

  • Jim Cramer Comparison Jim Cramer compared GRAIL to Moderna, drawing investor attention. This high-profile endorsement may have increased retail and institutional interest, contributing to stock momentum.

    Media attention can influence investor sentiment and demand for the stock, especially from retail investors.

  • Legal and Financial Risks Securities fraud lawsuits allege GRAIL misled investors about the NHS-Galleri trial, creating legal overhang. The company lost $110 million last quarter, and Galleri's ~$700 cost remains largely uncovered by insurers, so cash burn continues until approval and reimbursement arrive.

    These risks could weigh on the stock price and pose challenges to financial stability.

Latest
▲2▼1

FDA Panel Backs Galleri; Legal Overhang and Cash Burn Persist

  • FDA Panel Backs Galleri After Strong PATHFINDER 2 Data An FDA advisory panel voted 7-2 that Galleri's benefits outweigh risks, and PATHFINDER 2 showed it detected six times more cancers with few false alarms. This raises the odds of approval, which would open Medicare and insurer coverage and lift future sales.

    This is the biggest new positive catalyst for GRAL's price, directly advancing its path to approval and reimbursement.

  • Cramer Compares GRAIL to Moderna on Approval Potential Jim Cramer said GRAIL could climb much higher after the FDA panel vote, comparing it to Moderna. This kind of high-profile endorsement can draw new investor attention and buying interest, though it is opinion, not a change in the business itself.

    It is a new, widely followed bullish call that can move sentiment and demand for the stock.

  • High Cash Burn and No Insurance Coverage Limit Upside GRAIL lost $110 million last quarter and Galleri costs about $700 out of pocket, generally not covered by Medicare or private insurers yet. Until approval and reimbursement arrive, the company keeps burning cash, which is the biggest risk to the stock.

    It explains the key financial and adoption risk that could cap gains even if approval comes.

▲2▼1

FDA Panel Backs Galleri, but Securities Fraud Lawsuits Loom

  • FDA Panel Endorses Galleri On September 24, an FDA advisory panel voted 6-4 that Galleri is effective, 10-0 safe, and 7-2 benefits outweigh risks. This clears a major hurdle toward FDA approval, expected early 2027, which would open Medicare and private insurance coverage and boost future sales.

    This is the biggest new positive catalyst, directly advancing the path to insurance coverage and revenue growth.

  • Strong Q2 Galleri Volume and Revenue Growth GRAIL reported Q2 2026 Galleri test volume up 35% to over 61,000 and revenue up 24% to $42.6 million. Total revenue rose 26% to $44.7 million, and a $110 million equity investment from Samsung strengthened the balance sheet, showing growing demand and financial backing.

    This new data confirms commercial momentum and cash strength, supporting the stock's fundamental value.

  • Securities Fraud Lawsuits Over Trial Disclosures Multiple law firms filed or reminded investors of a securities class action alleging GRAIL misled investors about the NHS-Galleri trial's likelihood of success. The August 4 lead plaintiff deadline passed, but the lawsuit continues, creating legal overhang and potential financial penalties that could weigh on the stock.

    This is a new legal development that adds uncertainty and potential costs, a real counterweight to the positive news.

July 2026
▼2

GRAIL's Legal Overhang Deepens as August 4 Deadline Nears

  • Securities Fraud Lawsuits Keep Piling Up Multiple law firms have filed or are investigating securities fraud claims against GRAIL over the failed NHS-Galleri trial. The growing number of suits raises potential legal costs and keeps negative attention on the stock, weighing on the share price.

    This is the main new development this period, with several firms joining and a key deadline approaching.

  • August 4 Lead Plaintiff Deadline Looms Investors have until August 4, 2026 to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the news and may prompt more shareholders to come forward, sustaining pressure on GRAIL's stock.

    The deadline is a specific upcoming event that could drive further negative headlines and investor anxiety.

▼2

GRAIL's Legal Overhang Deepens as August 4 Deadline Nears

  • Securities Fraud Lawsuits Keep Piling Up Multiple law firms have filed or are investigating securities fraud claims against GRAIL over the failed NHS-Galleri trial. The growing number of suits raises potential legal costs and keeps negative attention on the stock, weighing on the share price.

    This is the main new development this period, with several firms joining and a key deadline approaching.

  • August 4 Lead Plaintiff Deadline Looms Investors have until August 4, 2026 to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the news and may prompt more shareholders to come forward, sustaining pressure on GRAIL's stock.

    The deadline is a specific upcoming event that could drive further negative headlines and investor anxiety.

Q2 2026
▼2

GRAIL Hit by Multiple Securities Fraud Lawsuits Over Failed NHS-Galleri Trial

  • Securities Fraud Class Action Filed A class action lawsuit accuses GRAIL and executives of misleading investors about the NHS-Galleri trial's ability to meet its goal. This legal fight could lead to fines or payouts, weighing on the stock.

    This is the first major lawsuit this period and directly threatens GRAIL's finances and reputation.

  • More Law Firms Join with Similar Suits Bronstein, Faruqi, Pomerantz, and Moore Law have all filed or announced investigations, each reminding investors of the August 4 deadline. The growing number of claims raises the potential legal costs and keeps negative attention on GRAIL.

    Shows the legal pressure is widening, not just a single firm, which increases uncertainty for the stock.

  • Galleri Misses Trial Goal but Still Pursues FDA Approval The Galleri test failed to reduce late-stage cancers in a large NHS trial, but GRAIL is still seeking FDA approval and insurance coverage. Management points to positive trends in 12 deadly cancers, which could support future revenue if insurers agree.

    This is the core clinical setback that triggered the lawsuits, but also the only potential positive path forward.

June 2026
▼2

GRAIL Hit by Multiple Securities Fraud Lawsuits Over Failed NHS-Galleri Trial

  • Securities Fraud Class Action Filed A class action lawsuit accuses GRAIL and executives of misleading investors about the NHS-Galleri trial's ability to meet its goal. This legal fight could lead to fines or payouts, weighing on the stock.

    This is the first major lawsuit this period and directly threatens GRAIL's finances and reputation.

  • More Law Firms Join with Similar Suits Bronstein, Faruqi, Pomerantz, and Moore Law have all filed or announced investigations, each reminding investors of the August 4 deadline. The growing number of claims raises the potential legal costs and keeps negative attention on GRAIL.

    Shows the legal pressure is widening, not just a single firm, which increases uncertainty for the stock.

  • Galleri Misses Trial Goal but Still Pursues FDA Approval The Galleri test failed to reduce late-stage cancers in a large NHS trial, but GRAIL is still seeking FDA approval and insurance coverage. Management points to positive trends in 12 deadly cancers, which could support future revenue if insurers agree.

    This is the core clinical setback that triggered the lawsuits, but also the only potential positive path forward.

▼2

GRAIL Hit by Multiple Securities Fraud Lawsuits Over Failed NHS-Galleri Trial

  • Securities Fraud Class Action Filed A class action lawsuit accuses GRAIL and executives of misleading investors about the NHS-Galleri trial's ability to meet its goal. This legal fight could lead to fines or payouts, weighing on the stock.

    This is the first major lawsuit this period and directly threatens GRAIL's finances and reputation.

  • More Law Firms Join with Similar Suits Bronstein, Faruqi, Pomerantz, and Moore Law have all filed or announced investigations, each reminding investors of the August 4 deadline. The growing number of claims raises the potential legal costs and keeps negative attention on GRAIL.

    Shows the legal pressure is widening, not just a single firm, which increases uncertainty for the stock.

  • Galleri Misses Trial Goal but Still Pursues FDA Approval The Galleri test failed to reduce late-stage cancers in a large NHS trial, but GRAIL is still seeking FDA approval and insurance coverage. Management points to positive trends in 12 deadly cancers, which could support future revenue if insurers agree.

    This is the core clinical setback that triggered the lawsuits, but also the only potential positive path forward.

Agilent Technologies Inc (A)

Q3 2026
▲3

Agilent Q3 Beat, China Rebound, Reshoring Orders Drive August Gains

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with 18% EPS growth and raised full-year guidance, sending shares up 9.6%. This shows the company is growing faster than expected and gives investors confidence in its momentum.

    This is the main new financial event that directly boosted the stock in August.

  • China rebound and reshoring orders China rebounded with double-digit pharma growth, and Agilent booked its first reshoring orders from five top-10 pharma companies. This reduces reliance on any single market and taps new demand as drug production moves closer to home.

    These are new geographic and customer wins that expand Agilent's revenue base.

  • Diagnostics expansion via FDA/EU approvals Agilent won FDA and EU approvals for PD-L1 cancer tests, expanding its diagnostics business. This opens new revenue streams in cancer care and strengthens its position in the fast-growing pathology market.

    New product approvals are concrete growth catalysts for the diagnostics segment.

  • AI and automation tailwinds vs. competition and sector sensitivity AI product launches, lab automation, and multi-year instrument replacement cycles add steady tailwinds. But Danaher's Leica is expanding in pathology, and the life sciences tools sector remains sensitive to growth-outlook cuts, which could cap gains if investors worry about market share or a broader slowdown.

    This captures both the positive long-term drivers and the real risks that could limit upside.

August 2026
▲3

Agilent Q3 Beat, China Rebound, Reshoring Orders Drive August Gains

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with 18% EPS growth and raised full-year guidance, sending shares up 9.6%. This shows the company is growing faster than expected and gives investors confidence in its momentum.

    This is the main new financial event that directly boosted the stock in August.

  • China rebound and reshoring orders China rebounded with double-digit pharma growth, and Agilent booked its first reshoring orders from five top-10 pharma companies. This reduces reliance on any single market and taps new demand as drug production moves closer to home.

    These are new geographic and customer wins that expand Agilent's revenue base.

  • Diagnostics expansion via FDA/EU approvals Agilent won FDA and EU approvals for PD-L1 cancer tests, expanding its diagnostics business. This opens new revenue streams in cancer care and strengthens its position in the fast-growing pathology market.

    New product approvals are concrete growth catalysts for the diagnostics segment.

  • AI and automation tailwinds vs. competition and sector sensitivity AI product launches, lab automation, and multi-year instrument replacement cycles add steady tailwinds. But Danaher's Leica is expanding in pathology, and the life sciences tools sector remains sensitive to growth-outlook cuts, which could cap gains if investors worry about market share or a broader slowdown.

    This captures both the positive long-term drivers and the real risks that could limit upside.

Latest
▲4

Agilent's Q3 beat and China/reshoring momentum drive shares higher

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with non-GAAP EPS up 18% and raised full-year guidance, sending shares up 9.6% since the report. Broad demand across pharma and China, plus Advanced Therapeutics up nearly 30%, shows the core business is accelerating and supports a higher stock price.

    This is the biggest new positive catalyst this period, directly driving the stock higher.

  • China strength and reshoring orders Management said China delivered double-digit growth in pharma and food and high-teens in advanced materials, and Agilent booked its first reshoring orders from five top-10 pharma companies. This opens a new demand source and supports long-term growth, pushing the stock up.

    New geographic and reshoring demand drivers that were not previously reported and directly boost growth outlook.

  • Instrument replacement cycle and lab automation Agilent is less than halfway through its liquid chromatography replacement cycle, worth 200-300 basis points of growth, and about a quarter through gas chromatography, worth 100 basis points. These multi-year upgrades plus lab automation provide a steady tailwind for revenue and the stock.

    New details on replacement cycles and automation that underpin future growth, not previously reported.

  • New AI product launches and investment Agilent launched a Gen5 AI cell identification module for BioTek imagers and led a multimillion-dollar investment in HALO X-ray Technologies. These moves expand its AI and security screening offerings, signaling innovation that can drive future sales and support the stock.

    New product and investment news that shows Agilent is advancing technology, a positive for future growth.

▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

Q2 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

June 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.